Boiron (FRA:BON) Tariff Resilience Score: 0/10 (As of Jul. 09, 2026)


FRA:BON Boiron SA FRA:BON
73 GF Score
Price €26.20
GF Value €33.52
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Boiron Tariff Resilience Score?

Boiron has the Tariff Resilience Score of 0, which implies that the company might have .

Boiron has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Boiron might have .

Boiron  (FRA:BON) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Boiron Tariff Resilience Score Related Terms

FRA:BON
73GF Score
Boiron SA FRA:BON
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Boiron (FRA:BON) Overvalued in 2026?

Based on GuruFocus' analysis, Boiron stock appears to be undervalued. The current stock price of €26.20 is trading 21.8% below its estimated GF Value™ of €33.52. GuruFocus considers Boiron to be Modestly Undervalued.

Key valuation signals for FRA:BON:

  • Tariff Resilience Score: 0
  • GF Value™: €33.52 vs. price of €26.20 (21.8% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the FRA:BON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Boiron Business Description

Other Exchanges BOIRF:USA0DTF:UKBOI:France
Address 2, Avenue de l’Ouest Lyonnais No. 039, Messimy, FRA, 69510
Boiron SA is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company's products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.
73GF Score

Get the complete analysis for FRA:BON

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€26.20
Price
€33.52
GF Value